David R. P. Almeida
David R. P. Almeida has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Eric. K. Chin
Retina Consultants of Southern California, Redlands, CA, USA
22 shared publications Eric K. Chin
Retina Consultants of Southern California, Redlands, CA, USA
18 shared publicationsKunyong Xu
Retina Consultants of Georgia, Augusta, GA, USA
11 shared publications- Vinit B. Mahajan
Molecular Surgery Laboratory, Stanford University, Palo Alto, USA
5 shared publications John B. Davies
Vitreoretinal Surgery PA, Minneapolis, Minnesota
4 shared publicationsD. Wilkin Parke
Vitreoretinal Surgery PA, Minneapolis, Minnesota
3 shared publications
Latest Publications
- 17 October 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
Intravitreal ONL1204 Ophthalmic Solution in Subjects With Macula-Off Rhegmatogenous Retinal Detachment
Purpose: To evaluate the safety and efficacy of ONL1204 as an adjunct to standard-of-care surgical repair in subjects with macula-off rhegmatogenous retinal detachment (RRD). Methods: A phase 2, randomized, sham-controlled, single-masked, dose-ranging, multicenter trial was performd in which participants received either a single intravitreal injection of ONL1204 (50 μg or 200 μg) or a sham injection before surgical repair of RRD. The primary endpoint was the mean area under the log contrast sensitivity function at week 24 for participants who did not have primary surgical failure. Key secondary endpoints included mean area under the log contrast sensitivity function at week 12 and mean best-corrected visual acuity (BCVA) at weeks 12 and 24. Results: One hundred thirty-six enrolled patients were randomized to receive 50 μg ONL1204 (n = 46), 200 μg ONL1204 (n = 45), or sham (n = 45). The primary endpoint was not met; no significant differences were seen in area under the log contrast sensitivity function and BCVA across the groups at weeks 12 or 24. Post-hoc subgroup analyses revealed that higher proportions of pseudophakic patients (88.2% vs 50.0%; P = .013) and patients with >8 days of macular detachment (47.4% vs 10.0%; P = .098) treated with 200 μg ONL1204 achieved 20/50 or better vision at 24 weeks vs sham. ONL1204 demonstrated a favorable safety profile. Conclusions: ONL1204 was observed to be safe and well-tolerated. Although the primary endpoint was not met, the potential remains for visual acuity outcomes to be enhanced in patients at higher risk of vision loss from RRD, such as those with an extended duration of macula-off status.
- 17 October 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
Intravitreal ONL1204 Ophthalmic Solution in Subjects With Macula-Off Rhegmatogenous Retinal Detachment
Purpose: To evaluate the safety and efficacy of ONL1204 as an adjunct to standard-of-care surgical repair in subjects with macula-off rhegmatogenous retinal detachment (RRD). Methods: A phase 2, randomized, sham-controlled, single-masked, dose-ranging, multicenter trial was performd in which participants received either a single intravitreal injection of ONL1204 (50 μg or 200 μg) or a sham injection before surgical repair of RRD. The primary endpoint was the mean area under the log contrast sensitivity function at week 24 for participants who did not have primary surgical failure. Key secondary endpoints included mean area under the log contrast sensitivity function at week 12 and mean best-corrected visual acuity (BCVA) at weeks 12 and 24. Results: One hundred thirty-six enrolled patients were randomized to receive 50 μg ONL1204 (n = 46), 200 μg ONL1204 (n = 45), or sham (n = 45). The primary endpoint was not met; no significant differences were seen in area under the log contrast sensitivity function and BCVA across the groups at weeks 12 or 24. Post-hoc subgroup analyses revealed that higher proportions of pseudophakic patients (88.2% vs 50.0%; P = .013) and patients with >8 days of macular detachment (47.4% vs 10.0%; P = .098) treated with 200 μg ONL1204 achieved 20/50 or better vision at 24 weeks vs sham. ONL1204 demonstrated a favorable safety profile. Conclusions: ONL1204 was observed to be safe and well-tolerated. Although the primary endpoint was not met, the potential remains for visual acuity outcomes to be enhanced in patients at higher risk of vision loss from RRD, such as those with an extended duration of macula-off status.
- Open Access
- 3 October 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Precision Monitoring of Vector Expression (PMVX) in Ocular Gene Therapy: Establish the Signature in Aqueous Humor, Test Whether Tears Can Maintain It (Preprint)
UNSTRUCTURED Gene therapies that make the eye secrete its own drug have no fixed dose. The dose is whatever the transduced cells produce, and it is rarely measured. Visual acuity and imaging show the consequences of expression; they do not show the protein. We propose precision monitoring of vector expression (PMVX), a three-step framework. First, an anterior chamber sample taken from every treated eye before and after dosing establishes a per-eye signature: the transgene product, its free target and a pre-specified downstream pathway. Second, tears collected on Schirmer strips at the same visits are compared with the aqueous, analyte by analyte, with fellow-eye tears and plasma as controls. Third, for analytes that pass, the strip is tested as a monitor between scheduled aqueous samples. The first step rests on published methods. The second and third are a hypothesis. No study has shown that tears report an intraocular transgene, and anatomy gives reasons to doubt it. We define the terms, set gates for each stage, and state the results that would prove the tear hypothesis wrong. The aqueous reference stands either way.
- 3 October 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessPrecision Monitoring of Vector Expression (PMVX) in Ocular Gene Therapy: Establish the Signature in Aqueous Humor, Test Whether Tears Can Maintain It (Preprint)
UNSTRUCTURED Gene therapies that make the eye secrete its own drug have no fixed dose. The dose is whatever the transduced cells produce, and it is rarely measured. Visual acuity and imaging show the consequences of expression; they do not show the protein. We propose precision monitoring of vector expression (PMVX), a three-step framework. First, an anterior chamber sample taken from every treated eye before and after dosing establishes a per-eye signature: the transgene product, its free target and a pre-specified downstream pathway. Second, tears collected on Schirmer strips at the same visits are compared with the aqueous, analyte by analyte, with fellow-eye tears and plasma as controls. Third, for analytes that pass, the strip is tested as a monitor between scheduled aqueous samples. The first step rests on published methods. The second and third are a hypothesis. No study has shown that tears report an intraocular transgene, and anatomy gives reasons to doubt it. We define the terms, set gates for each stage, and state the results that would prove the tear hypothesis wrong. The aqueous reference stands either way.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-5
The Final Millimeter: A Single-Center Retrospective Analysis of an Integrated Pneumatic Microinjection System for Subretinal Gene Therapy
- 1 May 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-5
Open AccessThe Final Millimeter: A Single-Center Retrospective Analysis of an Integrated Pneumatic Microinjection System for Subretinal Gene Therapy
- 27 April 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 10 (5) , 1040-1043
Safety and Efficacy of Vitreoretinal Office-Based Surgery: A Case Series of 173 Procedures in an Office-Based Suite
Purpose: To address the gap in safety and efficacy data for office-based vitreoretinal surgery by reporting outcomes from a significant case series performed in a specialized, independent, physician-owned office-based surgery suite. Methods: A retrospective, single-center case series of 173 consecutive vitreoretinal surgeries performed between January 1, 2025, and July 31, 2025, at the Center for Advanced Surgical Exploration in Erie, PA, a physician-owned, Joint Commission–accredited office-based surgery suite. Patient selection was restricted to American Society of Anesthesiologists systemic health classifications I and II. Procedures were conducted under minimal oral sedation and local anesthesia. Primary outcomes included rates of intraoperative and postoperative complications and hospital transfers. Results: A total of 173 patients (173 eyes) were included in the study. The procedural mix included rhegmatogenous retinal detachment repair (48/173, 27.7%), full-thickness macular hole repair (35/173, 20.2%), epiretinal membrane peel (58/173, 33.5%), and other complex procedures, including subretinal gene therapy administration with Port Delivery Platform implantation (32/173, 18.5%). No anesthesia-related complications or intraoperative events requiring hospital transfer occurred. The postoperative endophthalmitis rate was 0%. Other postoperative complications were observed at rates comparable to those reported for similar procedures in ambulatory surgery center settings. Conclusions: This series provides initial supporting evidence demonstrating that a carefully selected portfolio of complex vitreoretinal surgeries can be performed safely and effectively in a properly equipped and accredited office-based setting. With strict patient selection and anesthesia protocols, the office-based surgery model represents a viable evolution in the delivery of ophthalmic surgery.
- 27 April 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 10 (5) , 1040-1043
Safety and Efficacy of Vitreoretinal Office-Based Surgery: A Case Series of 173 Procedures in an Office-Based Suite
Purpose: To address the gap in safety and efficacy data for office-based vitreoretinal surgery by reporting outcomes from a significant case series performed in a specialized, independent, physician-owned office-based surgery suite. Methods: A retrospective, single-center case series of 173 consecutive vitreoretinal surgeries performed between January 1, 2025, and July 31, 2025, at the Center for Advanced Surgical Exploration in Erie, PA, a physician-owned, Joint Commission–accredited office-based surgery suite. Patient selection was restricted to American Society of Anesthesiologists systemic health classifications I and II. Procedures were conducted under minimal oral sedation and local anesthesia. Primary outcomes included rates of intraoperative and postoperative complications and hospital transfers. Results: A total of 173 patients (173 eyes) were included in the study. The procedural mix included rhegmatogenous retinal detachment repair (48/173, 27.7%), full-thickness macular hole repair (35/173, 20.2%), epiretinal membrane peel (58/173, 33.5%), and other complex procedures, including subretinal gene therapy administration with Port Delivery Platform implantation (32/173, 18.5%). No anesthesia-related complications or intraoperative events requiring hospital transfer occurred. The postoperative endophthalmitis rate was 0%. Other postoperative complications were observed at rates comparable to those reported for similar procedures in ambulatory surgery center settings. Conclusions: This series provides initial supporting evidence demonstrating that a carefully selected portfolio of complex vitreoretinal surgeries can be performed safely and effectively in a properly equipped and accredited office-based setting. With strict patient selection and anesthesia protocols, the office-based surgery model represents a viable evolution in the delivery of ophthalmic surgery.
- 5 April 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 10 (4) , 679-688
Preoperative Classification of Submembrane Spaces for Optical Coherence Tomography–Guided Epiretinal Membranectomy
Purpose: To evaluate optical coherence tomography (OCT)-guided epiretinal membrane (ERM) surgery using the preoperative retinal evaluation system for surgery classification in a retrospective, comparative case series. Methods : In a masked study, 137 eyes undergoing ERM surgery with this OCT-guided system were compared with 71 consecutive controls undergoing conventional surgery. Using spectral-domain OCT, ERMs were preoperatively classified into 4 categories based on submembrane space characteristics, allowing for a tailored surgical approach. Main outcomes included first-attempt success, surgical complications, and 3-month visual acuity. Results : Compared with controls, patients receiving our OCT-guided approach had significantly higher first-attempt success (89.2% vs 57.2%; P < . 001) and lower rates of petechial hemorrhage (40.0% vs 85.0%; P < . 001) and macular breaks (0% vs 8.0%; P < . 001). First-attempt success varied by class ( P < . 01), and mean operative time was reduced by 28% (19.6 vs 25.1 min; P < . 001). Visual improvement was significantly greater in the guided group at 3 months (+16.2 vs +11.2 ETDRS letters; P < . 01). Conclusions : The preoperative retinal evaluation system for surgery classification provides a practical framework for surgical planning in ERM cases. This OCT-guided approach helps stratify surgical risk, identify optimal engagement points, increase efficiency, and guide technique selection. Preoperative OCT-guided planning offers significant advantages over conventional methods, resulting in improved success rates and reduced complications.
- 5 April 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 10 (4) , 679-688
Preoperative Classification of Submembrane Spaces for Optical Coherence Tomography–Guided Epiretinal Membranectomy
Purpose: To evaluate optical coherence tomography (OCT)-guided epiretinal membrane (ERM) surgery using the preoperative retinal evaluation system for surgery classification in a retrospective, comparative case series. Methods : In a masked study, 137 eyes undergoing ERM surgery with this OCT-guided system were compared with 71 consecutive controls undergoing conventional surgery. Using spectral-domain OCT, ERMs were preoperatively classified into 4 categories based on submembrane space characteristics, allowing for a tailored surgical approach. Main outcomes included first-attempt success, surgical complications, and 3-month visual acuity. Results : Compared with controls, patients receiving our OCT-guided approach had significantly higher first-attempt success (89.2% vs 57.2%; P < . 001) and lower rates of petechial hemorrhage (40.0% vs 85.0%; P < . 001) and macular breaks (0% vs 8.0%; P < . 001). First-attempt success varied by class ( P < . 01), and mean operative time was reduced by 28% (19.6 vs 25.1 min; P < . 001). Visual improvement was significantly greater in the guided group at 3 months (+16.2 vs +11.2 ETDRS letters; P < . 01). Conclusions : The preoperative retinal evaluation system for surgery classification provides a practical framework for surgical planning in ERM cases. This OCT-guided approach helps stratify surgical risk, identify optimal engagement points, increase efficiency, and guide technique selection. Preoperative OCT-guided planning offers significant advantages over conventional methods, resulting in improved success rates and reduced complications.
- 25 October 2025
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 10 (1) , 177-179
Scleritis Secondary to Eosinophilic Granulomatosis With Polyangiitis
Purpose: To describe a case of severe scleritis with uveitis as the initial presentation of underlying eosinophilic granulomatosis with polyangiitis. Methods: Case report from a university ophthalmology clinic describing ocular findings, diagnostic workup, and treatment. Results: A 75-year-old woman presenting with severe anterior scleritis and panuveitis was initially misdiagnosed and treated for presumed infectious scleritis for 1 month without improvement. Further workup revealed elevated perinuclear anti-neutrophil cytoplasmic antibodies, supporting a diagnosis of eosinophilic granulomatosis with polyangiitis. Prompt initiation of high-dose oral corticosteroids led to rapid resolution of ocular inflammation. Conclusions: Severe scleritis with uveitis can be the first manifestation of occult eosinophilic granulomatosis with polyangiitis. A high index of suspicion for underlying autoimmune disease and timely rheumatologic workup are essential for accurate diagnosis. Early systemic immunosuppressive therapy is critical to optimize visual outcomes and prevent irreversible ocular damage.
- 25 October 2025
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 10 (1) , 177-179
Scleritis Secondary to Eosinophilic Granulomatosis With Polyangiitis
Purpose: To describe a case of severe scleritis with uveitis as the initial presentation of underlying eosinophilic granulomatosis with polyangiitis. Methods: Case report from a university ophthalmology clinic describing ocular findings, diagnostic workup, and treatment. Results: A 75-year-old woman presenting with severe anterior scleritis and panuveitis was initially misdiagnosed and treated for presumed infectious scleritis for 1 month without improvement. Further workup revealed elevated perinuclear anti-neutrophil cytoplasmic antibodies, supporting a diagnosis of eosinophilic granulomatosis with polyangiitis. Prompt initiation of high-dose oral corticosteroids led to rapid resolution of ocular inflammation. Conclusions: Severe scleritis with uveitis can be the first manifestation of occult eosinophilic granulomatosis with polyangiitis. A high index of suspicion for underlying autoimmune disease and timely rheumatologic workup are essential for accurate diagnosis. Early systemic immunosuppressive therapy is critical to optimize visual outcomes and prevent irreversible ocular damage.
- Open Access
- 29 September 2025
- Published by Publishing House Zaslavsky in Archive of Ukrainian Ophthalmology
- Vol. 13 (3) , 196-204
The first case of gene-independent genetic therapy for retinitis pigmentosa in a patient from the Ukrainian population
Background. Retinitis pigmentosa is a leading cause of blindness and low vision among young adults worldwide. Until recently, it was considered incurable; however, novel gene therapies can now halt disease progression and potentially improve vision. Currently, genetic therapies for inherited retinal diseases are not available in Ukraine. This article presents the clinical identification and first successful gene therapy of a Ukrainian patient with retinitis pigmentosa that was performed within a clinical trial in the USA. The purpose was to describe the critical need for ophthalmic genetic counseling (OGC) and the efficacy of the first case of gene-agnostic modifier gene therapy for retinitis pigmentosa in a patient from the Ukrainian population. Clinical case. The patient (a 33-year-old male) who was observed at the Top Clinic Denis underwent a comprehensive ophthalmic examination, including best-corrected visual acuity, indirect and direct ophthalmoscopy, fundus photography, fundus autofluorescence, pneumotonometry, perimetry, optical coherence tomography, electroretinography, genetic testing (Invitae Inherited Retinal Disorders Panel), and OGC. The treatment, a bilateral, single-dose subretinal injection of the gene-agnostic modifier OCU400-301 (Ocugen, Inc.), was administered at the Erie Retina Research (Pennsylvania, USA) as part of a Phase 3 clinical trial (NCT06388200). It was the first Ukrainian patient to receive gene therapy of the eye. This case demonstrates the utility of OGC as the “gold standard” for diagnosing genetically determined ophthalmic pathology. Specifically, the patient’s previous clinical diagnosis of Stargardt disease was reclassified to retinitis pigmentosa 39 via genetic testing. The patient was enrolled in the OCU400-301 clinical trial (NCT06388200). Short-term follow-up using OCT demonstrated structural preservation and outer retinal layer and photoreceptor layer thickening in both eyes. Conclusions. In cases of suspected inherited retinal diseases, it is critical to refer patients for OGC to confirm or reclassify the diagnosis and search for approved therapy or treatment within the framework of clinical trials on gene therapy of inherited retinal diseases. In this case, the gene-agnostic approach (OCU400-301 subretinal injection) demonstrated effective preservation of retinal structure and restoration of photoreceptors even in the short term after treatment of the first Ukrainian patient to receive ocular gene therapy in a US clinical trial.
- 29 September 2025
- Published by Publishing House Zaslavsky in Archive of Ukrainian Ophthalmology
- Vol. 13 (3) , 196-204
Open AccessThe first case of gene-independent genetic therapy for retinitis pigmentosa in a patient from the Ukrainian population
Background. Retinitis pigmentosa is a leading cause of blindness and low vision among young adults worldwide. Until recently, it was considered incurable; however, novel gene therapies can now halt disease progression and potentially improve vision. Currently, genetic therapies for inherited retinal diseases are not available in Ukraine. This article presents the clinical identification and first successful gene therapy of a Ukrainian patient with retinitis pigmentosa that was performed within a clinical trial in the USA. The purpose was to describe the critical need for ophthalmic genetic counseling (OGC) and the efficacy of the first case of gene-agnostic modifier gene therapy for retinitis pigmentosa in a patient from the Ukrainian population. Clinical case. The patient (a 33-year-old male) who was observed at the Top Clinic Denis underwent a comprehensive ophthalmic examination, including best-corrected visual acuity, indirect and direct ophthalmoscopy, fundus photography, fundus autofluorescence, pneumotonometry, perimetry, optical coherence tomography, electroretinography, genetic testing (Invitae Inherited Retinal Disorders Panel), and OGC. The treatment, a bilateral, single-dose subretinal injection of the gene-agnostic modifier OCU400-301 (Ocugen, Inc.), was administered at the Erie Retina Research (Pennsylvania, USA) as part of a Phase 3 clinical trial (NCT06388200). It was the first Ukrainian patient to receive gene therapy of the eye. This case demonstrates the utility of OGC as the “gold standard” for diagnosing genetically determined ophthalmic pathology. Specifically, the patient’s previous clinical diagnosis of Stargardt disease was reclassified to retinitis pigmentosa 39 via genetic testing. The patient was enrolled in the OCU400-301 clinical trial (NCT06388200). Short-term follow-up using OCT demonstrated structural preservation and outer retinal layer and photoreceptor layer thickening in both eyes. Conclusions. In cases of suspected inherited retinal diseases, it is critical to refer patients for OGC to confirm or reclassify the diagnosis and search for approved therapy or treatment within the framework of clinical trials on gene therapy of inherited retinal diseases. In this case, the gene-agnostic approach (OCU400-301 subretinal injection) demonstrated effective preservation of retinal structure and restoration of photoreceptors even in the short term after treatment of the first Ukrainian patient to receive ocular gene therapy in a US clinical trial.
- Open Access
- 2 September 2025
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 14 (9) , 6
Near-Real Surgical Specimens (NRSS): A Novel Platform for Standardized Assessment of Suprachoroidal Drug Delivery
Suprachoroidal (SC) drug delivery is a promising avenue for treating posterior segment ocular diseases. Current ex vivo models, primarily human cadaveric eyes, are limited by tissue variability and altered post-mortem fluid dynamics. We introduce near-real surgical specimens (NRSS), an engineered ocular tissue platform, to overcome these limitations and provide standardized, reproducible evaluation of SC drug delivery. NRSS ocular models were engineered with biomimetic properties calibrated to fresh human tissue. Suprachoroidal injections of a contrast-enhanced balanced salt solution (100 µL) were performed in NRSS specimens (n = 8) using the Everads Suprachoroidal Injector, which features a 30-gauge needle and a non-sharp nitinol tissue separator for tangential blunt dissection into the suprachoroidal space (SCS). An integrated contrast imaging system enabled real-time visualization. Key parameters, including SC coverage patterns, interspecimen variability (coefficient of variation [CV]), and injection dynamics, were quantified and compared to published human cadaveric eye data. The NRSS platform demonstrated consistent SC coverage patterns. With the Everads Suprachoroidal Injector, injectate exhibited an initial posterior diffusion from the injection site, followed by postero-circumferential spread. NRSS specimens showed significantly reduced inter-specimen variability in SC coverage compared to reported cadaveric studies (CV: 6.8% for NRSS vs. 17.7% for cadaveric tissue; P < 0.01). Real-time visualization provided detailed insights into the dynamic characteristics of SC injection, including fluid flow patterns and tissue interactions not readily observable in static cadaveric models. The NRSS platform offers a reproducible and standardized method for evaluating SC drug delivery, closely mimicking clinically relevant biomechanical properties. It enables direct visualization of injection dynamics and holds potential for customization to model pathologic conditions, providing distinct advantages over traditional cadaveric models for device testing, therapeutic assessment, and surgical training. The Everads Suprachoroidal Injector demonstrated effective and reliable access to the SCS in NRSS models with a characteristic posterior-first spread pattern. NRSS technology addresses critical limitations in current SC injection assessment models. It provides a robust, standardized platform for optimizing delivery devices, quantitatively evaluating novel therapeutics, and enhancing surgical training for SC procedures, thereby potentially accelerating the clinical translation of SC therapies.
- 2 September 2025
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 14 (9) , 6
Open AccessNear-Real Surgical Specimens (NRSS): A Novel Platform for Standardized Assessment of Suprachoroidal Drug Delivery
Suprachoroidal (SC) drug delivery is a promising avenue for treating posterior segment ocular diseases. Current ex vivo models, primarily human cadaveric eyes, are limited by tissue variability and altered post-mortem fluid dynamics. We introduce near-real surgical specimens (NRSS), an engineered ocular tissue platform, to overcome these limitations and provide standardized, reproducible evaluation of SC drug delivery. NRSS ocular models were engineered with biomimetic properties calibrated to fresh human tissue. Suprachoroidal injections of a contrast-enhanced balanced salt solution (100 µL) were performed in NRSS specimens (n = 8) using the Everads Suprachoroidal Injector, which features a 30-gauge needle and a non-sharp nitinol tissue separator for tangential blunt dissection into the suprachoroidal space (SCS). An integrated contrast imaging system enabled real-time visualization. Key parameters, including SC coverage patterns, interspecimen variability (coefficient of variation [CV]), and injection dynamics, were quantified and compared to published human cadaveric eye data. The NRSS platform demonstrated consistent SC coverage patterns. With the Everads Suprachoroidal Injector, injectate exhibited an initial posterior diffusion from the injection site, followed by postero-circumferential spread. NRSS specimens showed significantly reduced inter-specimen variability in SC coverage compared to reported cadaveric studies (CV: 6.8% for NRSS vs. 17.7% for cadaveric tissue; P < 0.01). Real-time visualization provided detailed insights into the dynamic characteristics of SC injection, including fluid flow patterns and tissue interactions not readily observable in static cadaveric models. The NRSS platform offers a reproducible and standardized method for evaluating SC drug delivery, closely mimicking clinically relevant biomechanical properties. It enables direct visualization of injection dynamics and holds potential for customization to model pathologic conditions, providing distinct advantages over traditional cadaveric models for device testing, therapeutic assessment, and surgical training. The Everads Suprachoroidal Injector demonstrated effective and reliable access to the SCS in NRSS models with a characteristic posterior-first spread pattern. NRSS technology addresses critical limitations in current SC injection assessment models. It provides a robust, standardized platform for optimizing delivery devices, quantitatively evaluating novel therapeutics, and enhancing surgical training for SC procedures, thereby potentially accelerating the clinical translation of SC therapies.
- Open Access
- 1 March 2025
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 19, 933-937
Virtual Reality Visual Field Testing in Glaucoma: Benefits and Drawbacks
Importance: Virtual reality-assisted visual field testing (VRVFT) is a novel modality for evaluating glaucoma progression, offering potential advantages over standard automated perimetry (SAP). To date, no narrative literature review has comprehensively discussed the benefits and drawbacks of VRVFT for glaucoma patients. Observations: A narrative literature review was conducted using PubMed and MEDLINE via EBSCOhost, covering articles published from 2014 to October 2023. The search terms used were “virtual reality visual field” AND “glaucoma”. Filters applied included “Free full text”, “Full text”, and “Peer Reviewed.” Inclusion criteria encompassed studies evaluating VRVFT in relation to glaucoma. Exclusion criteria included duplicates, meta-analyses, literature not discussing glaucoma or VRVFT, and other literature reviews. Sixteen studies met the inclusion criteria, comprising various study designs. VRVFT showed comparable reliability and efficacy to SAP in detecting glaucomatous visual field defects. Benefits of VRVFT included improved accessibility, patient comfort, and resource optimization. Drawbacks included technical limitations such as restricted luminance range, lack of sophisticated eye-tracking in some devices, and implementation challenges like patient technology familiarity and access to equipment. Conclusion: VRVFT presents several benefits, making it a promising alternative or complement to conventional glaucomatous visual field testing in outpatient clinics and remote settings. Addressing technical limitations and standardizing protocols are essential for broader clinical adoption.
- 1 March 2025
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 19, 933-937
Open AccessVirtual Reality Visual Field Testing in Glaucoma: Benefits and Drawbacks
Importance: Virtual reality-assisted visual field testing (VRVFT) is a novel modality for evaluating glaucoma progression, offering potential advantages over standard automated perimetry (SAP). To date, no narrative literature review has comprehensively discussed the benefits and drawbacks of VRVFT for glaucoma patients. Observations: A narrative literature review was conducted using PubMed and MEDLINE via EBSCOhost, covering articles published from 2014 to October 2023. The search terms used were “virtual reality visual field” AND “glaucoma”. Filters applied included “Free full text”, “Full text”, and “Peer Reviewed.” Inclusion criteria encompassed studies evaluating VRVFT in relation to glaucoma. Exclusion criteria included duplicates, meta-analyses, literature not discussing glaucoma or VRVFT, and other literature reviews. Sixteen studies met the inclusion criteria, comprising various study designs. VRVFT showed comparable reliability and efficacy to SAP in detecting glaucomatous visual field defects. Benefits of VRVFT included improved accessibility, patient comfort, and resource optimization. Drawbacks included technical limitations such as restricted luminance range, lack of sophisticated eye-tracking in some devices, and implementation challenges like patient technology familiarity and access to equipment. Conclusion: VRVFT presents several benefits, making it a promising alternative or complement to conventional glaucomatous visual field testing in outpatient clinics and remote settings. Addressing technical limitations and standardizing protocols are essential for broader clinical adoption.